Historically, commercial use of university research has been viewed in terms of spillovers. Recently, there has been a dramatic increase in technology transfer through licensing as universities attempt to appropriate the returns from faculty research. This change has prompted concerns regarding the source of this growth—specifically, whether it suggests a change in the nature of university research. (Thursby 2002) ^ University-based firms are receiving growing interest from policy makers and researchers. Such firms obtain a variety of tangible and intangible resources from their academic partners, and are expected to translate these advantages into substantial gains. (Bonardo 2011) ^Technology transfer is a big concern for universities, how can they identify business opportunities from IP developed? We have created relationships with universities to help them do just that. Contact us to learn more.
"At present, it is known that intangible resources, or intellectual capital, are the drivers of economic growth. IPStreet.com's tools can help you understand if your idea is patentable, how to patent an idea, how to conduct a patent search to it's full potential and understand the analytics behind the patent search. We can help with understanding patent duration, patent value and connecting you with an experienced patent lawyer. One of its components is the human resources. Human resources are the main source of knowledge of firms, and it is considered a critical resource, maybe the most important one (Johanson, 2005; Marr and Roos, 2005). For this reason, its management and its development are crucial to increase the value of the firm. The objective of this paper is to analyse the influence that the training expenses have over the total value of the intangibles. From the business management, the expenditure on training are an investment." (Lidia García-Zambrano et al). Let IPstreet.com help you with your HR Director needs.
Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.
Essential to understanding your portfolio, is to understand changes in your portfolio over time. Beyond merely counting the size of your portfolio as patents are granted and expired, you also need to consider other accumulation and growth patterns: velocity, momentum, claim quality, claim scope, geographic coverage (international), patent duration, patent analytics and patent fences or thickets. Using our patent search tools, such analyses are easy to do. Let IPstreet.com help you today.
(4) Words.
